trientine tetrahydrochloride

Trientine tetrahydrochloride is a small molecule copper chelating agent used for the treatment of Wilson's disease, a rare inherited disorder characterized by excessive accumulation of copper in the body. The drug acts by binding to excess copper, forming stable complexes that are excreted through urine, thereby reducing systemic copper levels. Additionally, it inhibits intestinal absorption of copper by chelating dietary copper within the gastrointestinal tract. Trientine tetrahydrochloride is indicated for adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. It was developed to address unmet needs in product stability and patient adherence and represents the first new drug approved for Wilson’s disease management in over 25 years[1][2][3][5][6].

Brand names

Cuvrior

Other names

trientinetriethylenetetramine tetrahydrochloride